Home
HelpTest Code MAGE4 Melanoma-associated antigen-A4 (MAGE-A4), Semi-Quantitative Immunohistochemistry, Manual
Shipping Instructions
Attach the green "Attention Pathology" address label (T498) to the outside of the transport container before putting into the courier mailer.
Necessary Information
A pathology/diagnostic report and a brief history are required.
Specimen Required
Specimen Type: Tissue
Supplies: Pathology Packaging Kit (T554)
Submit:
Formalin-fixed, paraffin-embedded tissue block
OR
3 Unstained glass, positively charged slides with 4-microns formalin-fixed, paraffin-embedded tissue
Additional Information: One slide will be stained with hematoxylin and eosin and returned.
Useful For
Determining expression of melanoma-associated antigen-A4 (MAGE-A4) in synovial sarcoma and other neoplasms
As an aid in screening patients who may be eligible for TECELRA (afamitresgene autoleucel) therapy
Method Name
Immunohistochemistry (IHC)
Reporting Name
MAGE-A4, SemiQuant IHC, ManualSpecimen Type
SpecialSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Special | Ambient (preferred) | |
| Refrigerated | ||
Reference Values
An interpretive report will be provided.
Interpretation
Melanoma-associated antigen-A4 (MAGE-A4) in synovial sarcomas is determined positive when there is at least moderate to strong cytoplasmic and/or nuclear staining in greater than or equal to 75% of tumor cells.(1)
This result should be interpreted in the appropriate clinical context.
Clinical Reference
1. Instruction manual: MAGE-A4 IHC 1F9 pharmDx Interpretation Manual-Synovial Sarcoma. Agilent Technologies, Inc; 08/29/2024
2. Caballero O, Chen Y. Cancer/testis (CT) antigens Potential targets for immunotherapy. Cancer Science 2009;100(11):2014-2021
3. Hong D, Van Tine B, Biswas S, et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients a phase 1 trial. Nature Medicine 2023;29:104-114
4. Wang T, Navenot JM, Rafail S, et al. Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A*02-eligible patients. Mol Ther Methods Clin Dev. 2024;32(2):101265. Published 2024 May 14. doi:10.1016/j.omtm.2024.101265
Day(s) Performed
Monday through Friday
Report Available
5 to 7 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88360
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MAGE4 | MAGE-A4, SemiQuant IHC, Manual | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 622998 | Interpretation | 59465-5 |
| 622999 | Participated in the Interpretation | No LOINC Needed |
| 623000 | Report electronically signed by | 19139-5 |
| 623001 | Material Received | 81178-6 |
| 623002 | Disclaimer | 62364-5 |
| 623003 | Case Number | 80398-1 |
Forms
If not ordering electronically, complete, print, and send a Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763) with the specimen.